Open AccessTreatment Lines in Hepatocellular Carcinoma
Author(s) -
Henning Wege,
Jun Li,
Harald Ittrich
Publication year - 2019
Publication title -
visceral medicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.598
H-Index - 17
eISSN - 2297-475X
pISSN - 2297-4725
DOI - 10.1159/000501749
Subject(s) - medicine , cabozantinib , hepatocellular carcinoma , liver transplantation , regorafenib , sorafenib , lenvatinib , ramucirumab , liver function , radiofrequency ablation , oncology , cirrhosis , liver cancer , clinical trial , malignancy , transplantation , cancer , colorectal cancer , ablation
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and the second most lethal malignancy worldwide. In the Western world, HCC predominantly develops in patients with liver cirrhosis. Therefore, application of locoregional interventions and systemic agents should be based on an interdisciplinary evaluation, most importantly, taking the functional liver reserve into account. This review summarizes current treatment lines and novel strategies in the management of HCC. For the most part, randomized controlled trials and large meta-analyses are reported, with an emphasis on systemic therapies.